Patent · US Active

Humanized AXL antibodies

US8841424B2 · kind B2 · utility

5Cited by

3References

11Claims

0Family size

Assignee

U3 Pharma GmbH · DE

Inventors

Peter Wirtz · Gauting, DE
Jens Ruhe · Martinsried, DE
Takeshi Takizawa · Tokyo, JP
Tomoko TAKAYAMA · Tokyo, JP

Key dates

Filing date	May 11, 2010
Grant date	Sep 23, 2014
Priority date	—
Expiry date	Oct 13, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.